Wake-Up Stroke: Clinical and Neuroimaging CharacteristicsSilva G.S.a, e · Lima F.O.a · Camargo E.C.S.a · Smith W.S.c · Singhal A.B.a · Greer D.M.a · Ay H.b · Lev M.H.b · Harris G.J.b · Halpern E.F.b · Sonni S.a · Koroshetz W.d · Furie K.L.a
Departments of aNeurology and bRadiology, Massachusetts General Hospital and Harvard Medical School, Boston, Mass., cDepartment of Neurology, University of California at San Francisco, San Francisco, Calif., and dNational Institute of Neurological Disorders and Stroke, Bethesda, Md., USA; eDepartment of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, Brazil Corresponding Author
Gisele Silva, MD
741 Altino Arantes Avenida apt 81
São Paulo, SP 04042-033 (Brazil)
Tel. +55 11 8358 0583, Fax +55 11 5083 2172
Background: Approximately 25% of ischemic stroke patients awaken with neurological deficits. In these patients, in whom the time from symptom onset is uncertain, brain imaging is a potential strategy to characterize the ischemia duration and the presence of salvageable brain tissue. Methods: We prospectively evaluated consecutive patients with acute ischemic stroke. CT angiography and CT perfusion (CTP) were performed in patients within 24 h of symptom onset. The patients were classified into ‘known onset’, ‘indefinite onset but not on awakening’ and ‘wake-up stroke’ groups. Results: Of 676 patients evaluated, 420 had known-onset strokes, 131 wake-up strokes and 125 strokes with an indefinite time of symptom onset. Ischemic lesion volumes were higher in patients with indefinite-onset strokes (p = 0.04). The frequencies of CTP mismatch and of large-vessel intracranial occlusions were similar among the groups (p = 0.9 and p = 0.2, respectively). Conclusion: The considerable prevalence of CTP mismatch and of intracranial artery occlusions in our patients with wake-up strokes suggests that arterial and perfusion imaging might be particularly important in this population. Revised indications for thrombolysis by using imaging-based protocols might offer these patients the prospect of receiving acute stroke treatment even without a clear time of symptom onset.
© 2010 S. Karger AG, Basel
Approximately 25% of patients with ischemic stroke awaken with neurological deficits . Although some of these patients might be good candidates to receive acute treatment, they are not eligible for thrombolysis because of the uncertain time of stroke onset . A retrospective analysis of the off-label use of thrombolytic therapy in wake-up strokes did not show an increased risk of intracranial bleeding, suggesting that at least a subset of those patients could benefit from reperfusion therapies . Conversely, a randomized controlled trial of abciximab in acute ischemic stroke led to a higher risk of hemorrhagic transformation in patients with wake-up strokes than in patients with a definite onset time . Therefore, if reperfusion therapies are to be used in patients with wake-up stroke, it is important to carefully select patients that more likely will benefit from treatment.
Neuroimaging techniques may allow an estimation of potential benefits and risks of therapies aiming at restoring perfusion . Ischemic lesion volumes, and the presence of intracranial artery occlusions and of potentially salvageable brain tissue are neuroimaging characteristics that might influence the decision to treat ischemic stroke patients with reperfusion therapies . Knowledge of the volume of the ischemic lesion might help estimate the risk for hemorrhagic transformation after reperfusion because lesions with higher volumes are more prone to hemorrhagic transformation . In addition to detecting the presence of intracranial artery occlusions, CT angiography (CTA) can estimate ischemic lesion volumes via an analysis of CTA source images (CTA-SI). CTA-SI correlate with lesion volumes on diffusion-weighted imaging and may have advantages over other techniques because CTA-SI cover the entire brain and are available at the completion of imaging . The perfusion/diffusion mismatch is a surrogate marker of salvageable brain tissue and of the time of stroke onset, considering that the amount of mismatch declines with the time from symptom onset . The CT perfusion (CTP) cerebral blood flow/cerebral blood volume (CBF/CBV) mismatch is comparable to the perfusion/diffusion mismatch for the evaluation of cerebral penumbra in acute ischemic stroke .
In wake-up strokes, findings on CTA and CTA-SI, and the prevalence of CTP mismatch have not been studied. Our objective was to describe the clinical, CTA, CTA-SI and CTP characteristics of patients with wake-up strokes, and to compare these findings with those of patients with a known time of onset and indefinite onset time due to the lack of a witness.
We evaluated consecutive patients enrolled in a prospective cohort study at 2 university-based hospitals from March 2003 to December 2005. Noncontrast CT (NCCT) scans, CTA and CTA-SI were performed for suspected ischemic stroke within 24 h from symptom onset or from last seen well. Patients with intracranial hemorrhage or an alternative cause of the neurological symptoms, and those in whom iodinated contrast administration was contraindicated (i.e. contrast allergy, pregnancy, congestive heart failure and glomerular filtration rate <30 ml/min) were excluded. CTP was performed within 12 h of symptom onset or last seen well unless the treating neurologist contraindicated the additional dose of contrast. CT, CTA and CTP were performed at the same session for each patient. The data collected included demographics, National Institute of Health Stroke Scale (NIHSS) scores, modified Rankin Scale (mRS) scores before stroke, at discharge and at 6 months, Stop Stroke Study-TOAST (SSS-TOAST) and Oxfordshire community stroke project classifications, neuroimaging characteristics and thrombolysis status . The patients were classified into 3 groups based on the circumstance of symptom identification: known-onset strokes (recognized by the patient or by a witness), indefinite-onset strokes but not on awakening (unknown onset time due to the lack of a witness when the patient was unable to determine the time of symptom onset), and wake-up strokes (symptoms on awakening recognized by a witness or by the patient) . The prospective study received institutional review board approval. All participants provided their written informed consent.
NCCT and CTA acquisitions were performed with 16- or 64-section multidetector CT scanners (Lightspeed; GE Healthcare, Milwaukee, Wisc., USA). Representative sample parameters were 120–140 kVp, 170 mA, scan time = 2 s and section thickness = 5 mm for NCCT. CTA was performed 25 s after the intravenous administration of 100–140 ml of a nonionic contrast agent (Isovue; Bracco Diagnostics, Princeton, N.J., USA) by power injector at 3 ml/s (Medrad Power Injector; Medrad, Indianola, Pa., USA) . The parameters were 140 kVp, 220–250 mA, rotation time = 0.8–1.0 s, section thickness = 2.5 mm, reconstruction interval = 1.25 mm, 3.75 mm per rotation table speed and 0.75:1 pitch. Immediately afterward, a second set of images was obtained from the aortic arch to the skull base. Source images were reconstructed into standardized maximum intensity projection views of the intracranial and extracranial vasculature.
CTP was initiated 5 s after the administration of 45 ml of contrast at 7 ml/s. Four contiguous, 5-mm-thick CT slices were acquired simultaneously every second, during 45–60 s. The postprocessing of CBF and CBV maps was done using the software CT Perfusion 3 (GE Healthcare) .
The images were analyzed by consensus by a neuroradiologist and 2 neurologists experienced in stroke neuroimaging. The reviewers were blinded to the patients’ clinical characteristics and to the CTA-SI and follow-up CT studies performed for each patient when evaluating the presence of a CBF/CBV mismatch. Brain magnetic resonance imaging (MRI) was performed as indicated on clinical grounds in selected patients, but it was not a part of the research protocol and was not available to the reviewers when CT, CTA and CTP were being evaluated. Axial CTA-SI were evaluated for ischemic regions by identifying areas of relative hypoattenuation. Using a semiautomated software (Alice; Parexel, Waltham, Mass., USA), these regions were visually segmented to determine the total lesion volume . CTA was used to assess for arterial stenoses and occlusions. Large intracranial vessel occlusions amenable to intra-arterial neurointerventional approaches were defined as middle cerebral artery (M1 or proximal M2), internal carotid artery or basilar occlusions when those arteries were the culprits in the acute stroke . Hemorrhagic transformation was defined as any apparently extravascular blood in the brain or within the cranium, and was classified as symptomatic if associated with clinical deterioration as defined by an increase of 4 points or more on the NIHSS .
CTP was analyzed for the presence of a CBF/CBV mismatch by visual inspection. A mismatch was defined as at least 25% larger perfusion abnormality (measured by CBF) compared with the CBV deficit. CTP scans that did not cover the maximal area of the expected perfusion abnormality were excluded. Additionally, to avoid overestimating perfusion deficits due to bolus-tracking time delay, we excluded CTP of patients with atrial fibrillation and of patients with cervical internal carotid artery occlusions ipsilateral to the stroke.
Means and SD, or medians and interquartile intervals were used to describe the patients’ characteristics. One-way ANOVA and the Kruskal-Wallis test were used for the comparison of continuous parametric and nonparametric variables, respectively. The Mann-Whitney test with Bonferroni correction was used to compare the different groups against the definite-time group. Categorical comparisons were made by the χ2 or Fisher exact test. We used logistic regression analysis to investigate the influence of the circumstance of stroke symptom identification (known onset, indefinite onset and wake-up stroke) upon 6 months mRS scores dichotomized at 2 (mRS ≤2 vs. >2), with adjustment for age, sex, prestroke mRS score, NIHSS score at admission, volume of ischemic lesion, and thrombolytic therapy. p < 0.05 was considered significant. SPSS (SPSS, Chicago, Ill., USA) was used for the calculations.
Of 676 patients evaluated from March 2003 to December 2005, 420 patients had known-onset, 125 indefinite-onset and 131 wake-up strokes. The known-onset and wake-up stroke groups did not differ significantly in age, gender, NIHSS score at admission or SSS-TOAST subtype. Patients with indefinite-onset strokes were predominantly female, older and had higher NIHSS scores at admission (table 1). The time interval from stroke symptom onset (or from last seen well) to first neuroimaging was longer in patients with wake-up and indefinite-onset strokes compared to those with known-onset stroke. Twenty percent of the patients had posterior circulation strokes, 16.8% total anterior circulation strokes, 44.4% partial anterior circulation strokes and 18.8% lacunar strokes. There was no difference in the frequency of Oxfordshire classification subtypes between the 3 different groups of stroke symptom recognition (p = 0.42).
CTA and CTA-SI were available for all patients. The large vessel intracranial occlusions amenable to intra-arterial neurointerventional approaches (M1 and proximal M2, internal carotid artery or basilar arteries) were similar among the 3 groups (fig. 1; table 2). The CTA-SI lesion volumes were higher in patients with indefinite-onset strokes than in patients with known-onset strokes. There were no differences in ischemic lesion volumes between the patients with wake-up and known-onset strokes (table 1; fig. 2).
A total of 393 patients (58%) underwent CTP at baseline. We excluded 186 CTP from the analysis due to lack of coverage of the maximal area of the expected perfusion abnormality, 32 due to atrial fibrillation at admission and 7 due to cervical internal carotid artery occlusions ipsilateral to the stroke. The frequency of CTP exams was similar among the 3 groups both before and after excluding poor-quality exams (p = 0.2 and p = 0.3, respectively). In the 170 CTP evaluated, the frequency of CBF/CBV mismatch was not significantly different among the groups (table 1; fig. 1).
The patients with indefinite-onset or wake-up strokes who presented within a 3-hour window from last seen well and were eligible received intravenous tissue plasminogen activator. An 8-hour window was used for intra-arterial approaches to revascularization. Patients with known onset were more frequently treated with intravenous tissue plasminogen activator (p < 0.01). There was no difference in the frequency of symptomatic hemorrhagic transformations between the 3 different groups of stroke symptom recognition (table 1). The patients with indefinite-onset strokes had a higher frequency of asymptomatic hemorrhagic transformations when compared to patients with known-onset strokes (p < 0.01). In the patients treated with intravenous thrombolysis, there was no difference in the frequency of symptomatic or asymptomatic hemorrhagic transformations between the 3 groups.
The patients with indefinite onset had the poorest outcomes at discharge, with only 32% achieving an mRS score of 0–2, compared to 48% in the other groups (p < 0.01) (fig. 1). At 6 months, after adjustment for age, sex, prestroke mRS, NIHSS score at admission, the volume of ischemic lesion, and thrombolytic therapy, the circumstance of stroke symptom identification was no longer a predictor of mRS scores (p = 0.38). Treatment with intravenous thrombolysis, male sex, lower prestroke mRS scores, stroke volumes and NIHSS scores at admission were all predictors of good functional outcome (mRS scores of 0–2) at 6 months.
In the present study, we found that patients with wake-up and known-onset strokes were clinically similar. Patients with indefinite onset, however, had more severe deficits at admission, different clinical characteristics and a worse prognosis at discharge.
Patients with indefinite-onset strokes, but not those with wake-up strokes, had higher volumes of ischemic lesion when compared to patients with known-onset strokes. The frequency of CBF/CBV mismatch, however, was similar, irrespective of the circumstance of stroke symptom identification. In acute ischemic stroke, ischemic lesion volume grows with time from symptom onset and might therefore be used as a marker of ischemia duration . Although the exact time of symptom onset was unclear for both wake-up and indefinite-onset strokes, in patients with wake-up strokes less time might have elapsed from the onset of stroke. Circadian variation is well described for strokes, with the most cerebrovascular events witnessed happening during the morning . It is possible that some patients who wake up with symptoms had their stroke onset close to the time of arousal and could therefore benefit from reperfusion therapies.
The progression of ischemic lesions into the penumbra area has been described to occur beyond 3 h of symptom onset [17,18]. Furthermore, the reperfusion of an area of initial hypoperfusion has been associated with a reduced infarct growth and favorable clinical outcome [17,18]. Consequently, neuroimaging is a potentially powerful tool to identify patients with uncertain onset time that could possibly benefit from thrombolysis. Since the frequency of mismatch was similar in the 3 groups, and mismatch is a surrogate marker of tissue viability, it can be inferred that a similar proportion of patients from all 3 groups had ischemic penumbra potentially salvageable by reperfusion . Nevertheless, the risk/benefit ratio of thrombolytic therapy would likely be unfavorable to indefinite-onset patients because of the larger ischemic lesions and consequently increased risk of hemorrhagic transformation and poor clinical outcome . In fact, asymptomatic hemorrhagic transformation was more common in patients with an indefinite onset time in our series. Possible explanations for this finding include greater ischemic volumes in this group, higher rates of treatment with intra-arterial thrombolysis and, likely, more time elapsed from stroke onset. Our results are in accordance with those from the study of Fink et al. , which demonstrated, by using MRI, that a similar proportion of known-onset and wake-up strokes have imaging parameters compatible with the presence of salvageable tissue. Other authors showed that patients with indefinite stroke onset time, even when evaluated within 3 h of stroke recognition, are more likely to have definite hypodense areas on NCCT when compared to wake-up and known-onset strokes .
Wake-up strokes had outcomes at hospital discharge similar to those of known-onset strokes despite the higher percentage of patients treated with thrombolytics in known-onset strokes. Although similar outcomes in wake-up and known-onset strokes have been previously reported, a recent randomized controlled trial showed that abciximab can lead to a worse prognosis in wake-up strokes when compared to known-onset strokes . The administration of abciximab, however, was not based on neuroimaging characteristics with a favorable risk/benefit ratio for reperfusion therapies . In our study, the poorer outcomes of patients with indefinite-onset strokes when compared to patients with known-onset strokes were explained by more severe deficits at admission (higher NIHSS scores), older age, female sex, larger ischemic lesion volumes and a lower frequency of treatments with intravenous thrombolytic therapy, all predictors of outcome following ischemic stroke in other series .
This study has a number of limitations. First, CTP was performed in a subset of approximately 60% of the patients. Patients who did not have a CTP done, however, were clinically similar to patients evaluated by CTP, except that most were more than 12 h from symptom onset or from last seen well, because CTP was routinely performed only within 12 h of stroke symptom onset. The similar frequency of CTP exams among the 3 groups, however, suggests that there was no systematic bias regarding groups. Therefore, our CTP data are likely generalizable to the subset of patients who present to the hospital within 12 h from symptom onset or from last seen well. Secondly, the presence of a CTP mismatch suggests, but does not prove, tissue viability . Although there is good evidence that patients with MRI perfusion/diffusion-weighted imaging mismatch at presentation seem to benefit from reperfusion therapies, a definitive study in which the therapeutic window is based on the presence of mismatch only, and not on the time from symptom onset, is still lacking . The ideal definition and measurement of mismatch using CTP and MRI are not completely established. Perfusion imaging parameters which indicate that tissue is at risk for infarction and could potentially have clinical relevance or that adequate reperfusion has occurred are still undetermined as well . Therefore, we cannot extrapolate the safety or efficacy of reperfusion therapies in patients with wake-up strokes based on our data. We used only visual inspection in order to determine mismatch presence. Although quantitative methods would be ideal to measure the extent of ischemic penumbra, visual inspection is practical in the acute setting and more reflective of real life acute stroke practice .
The considerable prevalence of CTP mismatch and of intracranial artery occlusions in our patients with wake-up strokes suggests that arterial and perfusion imaging might be particularly important in this population. Revised indications for thrombolysis, using imaging-based protocols, might offer these patients the prospect of receiving acute stroke treatment even without a clear time of symptom onset .
This study was supported by NIH grant AHRQ R01 HS11392 (K.L.F.).
Gisele Silva, MD
741 Altino Arantes Avenida apt 81
São Paulo, SP 04042-033 (Brazil)
Tel. +55 11 8358 0583, Fax +55 11 5083 2172
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.